Table 1.
Subject characteristics.
| Characteristic | Controls (n=34) | AS (n=26) | IS (n=24) | p value |
|---|---|---|---|---|
| Age, years | 44.3 ± 12.5 | 46.7 ± 12.7 | 52.3 ± 13.6 | 0.08 |
| Female (n (%)) | 17 (50%) | 12 (46.6%) | 14 (58.3%) | 0.7 |
| Current and ex-smoker (n (%)) | 8 (22.8%) | 7 (26.9%) | 6 (25%) | 0.9 |
| ACE (UI/L) (mean ± SD) | NA | 119.3 ± 58 | 62 ± 30.5 | <0.0001 |
| Extra thoracic involvement (n (%)) | NA | 13 (50%) | 12 (50%) | 1 |
| Scadding CXR stage (n (%)) | ||||
| 0 | NA | 0 (0%) | 4 (16.6%) | <0.0001 |
| 1 | 1 (3.8%) | 12(50%) | ||
| 2 | 18 (69.2%) | 2 (8.3%) | ||
| 3 | 1 (3.8%) | 1 (4.1%) | ||
| 4 | 6 (23.1%) | 5 (20.8%) | ||
| Pulmonary function | ||||
| FVC % [predicted; mean ± SD] | NA | 77.6 ± 21.6 | 94.2 ± 19 | 0.006 |
| DLCO % [predicted; mean ± SD] | 58 ± 20.6 | 74.5 ± 14.2 | 0.003 | |
| Treatment initiation* (n (%)) | NA | 18 (69.2%) | 5 (20.8%) | 0.0009 |
| aCTAS [32] (n (%)) | NA | |||
| 0 | 0 (0%) | 11 (45.8%) | ||
| 1 | 0 (0%) | 13 (54.2%) | ||
| 2 | 18 (69.2%) | 0 (0%) | ||
| 3 | 8 (30.7%) | 0 (0%) | ||
| 4 | 0 (0%) | 0 (0%) |
Data are expressed in mean ± SD or N (%); groups were compared for continuous variables with one-way ANOVA test (3 groups) or t-student test (2 groups) and for categorical variables with Chi2 test; *Immunosuppressive or corticosteroid treatment initiation ≤ 6 months after inclusion. AS, high active sarcoidosis, IS, low active or inactive sarcoidosis ACE, angiotensin converting enzyme; CXR, chest x-ray; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; aCTAS, abbreviated CT activity Score (32); NA, not applicable.
Bold characters highlight significant values.